8 big new drugs on the market this year! Tumors, diabetes, eye disease... The patient's gospel.

(Health Times reporter Yang Yue
)
2018, a large wave of imported and domestic new drugs through the priority review channel was approved for listing. This year is not only imported drugs, domestic innovation drugs also show no weakness. As of May 2018, eight important products have been approved for sale in The Fields of Development, Bayer, Hengrui, Mercado, Xi'an Jansen and AstraZeneca, covering diseaseareas such as cancer, diabetes, aggressive spina bifida, ophthalmology, and assisted reproduction.
:
heavy-duty first generic izede of assisted reproduction
research and development of pharmaceutical enterprises: Zhengda qing
applicable population: accept assisted reproduction women
Zhengda Qing obtained the State Drug Administration registered for the drug acetic acid ganirik injection (Clear Music), is used in the field of assisted reproduction, its adaptation to the population for women receiving assisted reproductive technology controlled ovarian stimulation program, for example, for women who are undergoing IVF, the main effect of acetic acid
original research and development by Mercatoon, the product named Orgalutran, entered China in June 2013, currently only 10 provinces won the bid, the winning bid of 360 yuan / branch. The price of the drug is expected to fall as generic drugs are available, the first generic drug in the country.
with the Chinese's age of birth and the liberalization of the second child policy, more and more women will need assisted reproductive therapy.
:
ophthalmology field added new
research and development of pharmaceutical companies: Bayer
adapted to the population: age-related macular degeneration patients
May 8, the National Drug Administration approved Bayer's Abesip intra-eye injection solution (Alya) for the treatment of adult newborn blood vessels (wet) age-related macular degeneration (nAMD).
three months ago, the drug was also approved for the treatment of diabetic macular edema (DME), and is the only anti-VEGF drug currently approved in China to treat diabetic macular edema. The products related to injection solution in the abethip eye have been listed in more than 100 countries.
at home, Bayer's Alya will form a three-strong competition situation with Novartis's Rayju Zuma, Kanghong's Compaqip, and in 2017, after the National People's Social Administration's drug price negotiations, The Rejuiton resistance fell from 7,125 yuan/branch to 5,700 yuan, a 20% drop;
Aido:
long-acting drugs to alleviate the pain of chemotherapy
research and development enterprises: Jiangsu Hengrui
to adapt to the population: chemotherapy-related neutropenia cell reduction patients
Hengrui Pharmaceuticals issued a notice that recently received the CFDA approved the issuance of the sulfur-pistin injection (Ado) "new drug certificate" and "drug registration approval", which also indicates that Ado has been approved.
thiopheic non-gestin is a polyethyl glycolrecine-concentrated stimulator (referred to as long-acting G-CSF), which is the first clinical guideline spent at home and abroad, and is used in chemotherapy-related neutropenia-related treatment drugs, including short-acting and long-acting two types.
short-acting G-CSF in each chemotherapy cycle needs to be administered 1 to 2 times a day, long-acting G-CSF is mainly prepared by polyglycol modification, in a chemotherapy cycle often only need to administer 1 time, can greatly improve patient compliance, thereby reducing the patient's pain and burden.
essenatide microspheres:
a small microsphere
research and development of pharmaceutical companies: AstraZeneca
adapt editing population: type 2 diabetes people
daily need to take drugs, injections to bring pain will make long-term drug compliance of diabetic patients reduced, resulting in a decline in the efficacy of sugar control drugs.On January 4,
, Sansheng Pharmaceuticals announced that its injectable essennapeptide microsphere (Baidayan) has been approved for sale, considered china's first weekly drug, glucagon-like peptide-1.
"GLP-1 receptor agonist weekly preparation sat in China, providing a weekly long-acting sugar reduction treatment model for diabetics, is expected to further improve the control rate of type 2 diabetes in China. "Professor Ji Linon of Peking University People's Hospital, lead researcher of the Asian Clinical Study of Essena peptide microsphere III, said. It is understood that the drug was developed by AstraZeneca, in October 2017 Sansheng Pharmaceuticals for $100 million to obtain the exclusive commercial rights of this series of drugs in China, valid for 20 years.
Fucovi:
new gospel of lung cancer patients
research and development of pharmaceutical companies: Zhengda Qing
adapt to the population: non-small cell lung cancer patients
Zhengda Qing in May this year, two heavy new drugs were approved for the market, respectively, anrotinib hydrochloric acid (Focovi) and acetate ganirik injections (Clear Music).
Fucovi is used in the treatment of non-small cell lung cancer, which has the dual effect of anti-tumor angiogenesis and inhibits tumor growth. According to zhengda Tianqing official information, clinical trials confirmed that Focovi is currently the only advanced non-small cell lung cancer anti-angiogenesis targeted drugs in a single effective oral preparation, adverse reactions are light, well-tolerated, is expected to become the advanced non-small cell lung cancer patients three-line treatment standard drug.
nine price Jiadashu:
8 days of light speed approved cervical cancer vaccine
research and development pharmaceutical enterprises: Mersadong
applicable population: 16 to 26 years old female
this year, Mercadong's nine-price cervical cancer vaccine (Jiadaxiu) set a new record for approval, from the application to the time of approval is only 8 days. The 9-price HPV vaccine approval speed is unprecedented, and is known in the industry as "rocket speed". It is reported that, thanks to a number of drug review new policies, the 9-price vaccine was quickly approved.On May 30,
, the first batch of nine-valent HPV vaccine Chinese mainland was launched at Boao Super Hospital and Harmony Home Medical Center in Hainan, with a total cost of 5,800 yuan for doctor consultation, health check-ups, and three doses of nine-price cervical cancer vaccination services.
:
oral antiviral hepatitis C drug Gemini
research and development of pharmaceutical companies: Mersadon
suitable population: Gene 1, 4 chronic hepatitis C adult patients
Elbavegrariver (Choose Byda), is an oral direct antiviral drug approved on April 28 this year, the drug is the industry called chronic hepatitis C treatment "Gemini" new combination, is composed of elbave (elbas) At present, the competition for new drugs for hepatitis C is fierce, and in 2017 many new drugs for hepatitis C will enter the Chinese market, including The uinth-century Squibb's dalatevir and Ashureve softgels, Gilead, Abbvie's oral new drug Sofibwe tablets, Obi-Palli tablets, etc.
Himponi:
once a month injection of positive positive straight patients
research and development of pharmaceutical companies: Xi'an Yangsen
adapt ingenal population: active strong direct spina bifida patients
monthly, subcutaneous injection can alleviate joint pain in patients with aggressive spina bifida, improve quality of life, this is China's first monthly subcutaneous injection of anti-rheumatoid bio-preparation Golimu monoanti-injection injection (Himponi)
hampuni is mainly used for the treatment of adult patients with active scoliosis, but also in combination with methotrexate (MTX) treatment of adult patients with moderate to severe active rheumatoid arthritis who have poor efficacy of anti-rheumatoid drugs, including MTX.
.